M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
17.34 EUR
0 (0%)
M12 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 32 industry peers in the Health Care Providers & Services industry. M12 gets an excellent profitability rating and is at the same time showing great financial health properties. M12 has a correct valuation and a medium growth rate. These ratings could make M12 a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
- M12 had positive earnings in the past year.
- In the past year M12 had a positive cash flow from operations.
- Each year in the past 5 years M12 has been profitable.
- Each year in the past 5 years M12 had a positive operating cash flow.
1.2 Ratios
- M12 has a Return On Assets of 8.73%. This is amongst the best in the industry. M12 outperforms 96.88% of its industry peers.
- With a decent Return On Equity value of 15.03%, M12 is doing good in the industry, outperforming 78.13% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 13.44%, M12 belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
- M12 had an Average Return On Invested Capital over the past 3 years of 7.72%. This is in line with the industry average of 7.02%.
- The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
- With an excellent Profit Margin value of 5.00%, M12 belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
- In the last couple of years the Profit Margin of M12 has declined.
- The Operating Margin of M12 (8.52%) is better than 81.25% of its industry peers.
- In the last couple of years the Operating Margin of M12 has declined.
- M12 has a Gross Margin (19.29%) which is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so M12 is creating value.
- M12 has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for M12 has been increased compared to 5 years ago.
- M12 has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.62 indicates that M12 is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.62, M12 belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
- M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.70, M12 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
- M12 has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.62 |
ROIC/WACC1.87
WACC7.2%
2.3 Liquidity
- A Current Ratio of 2.06 indicates that M12 has no problem at all paying its short term obligations.
- The Current ratio of M12 (2.06) is better than 93.75% of its industry peers.
- M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.35, M12 belongs to the top of the industry, outperforming 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 10.36% over the past year.
- The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
- M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
- Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
- M12 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.18% yearly.
- Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 8.24% on average per year.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 18.45, the valuation of M12 can be described as rather expensive.
- M12's Price/Earnings ratio is in line with the industry average.
- The average S&P500 Price/Earnings ratio is at 27.47. M12 is valued slightly cheaper when compared to this.
- Based on the Price/Forward Earnings ratio of 14.95, the valuation of M12 can be described as correct.
- The rest of the industry has a similar Price/Forward Earnings ratio as M12.
- M12 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.45 | ||
| Fwd PE | 14.95 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, M12 is valued a bit cheaper than the industry average as 65.63% of the companies are valued more expensively.
- M12's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.76 | ||
| EV/EBITDA | 8.49 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- M12 has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as M12's earnings are expected to grow with 19.18% in the coming years.
PEG (NY)3.55
PEG (5Y)2.32
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 2.88%, M12 has a reasonable but not impressive dividend return.
- M12's Dividend Yield is rather good when compared to the industry average which is at 1.57. M12 pays more dividend than 87.50% of the companies in the same industry.
- M12's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.88% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (1/16/2026, 7:00:00 PM)
17.34
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-18 2025-11-18
Earnings (Next)05-19 2026-05-19
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap340.56M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target28.05 (61.76%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.88% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.45 | ||
| Fwd PE | 14.95 | ||
| P/S | 0.96 | ||
| P/FCF | 12.76 | ||
| P/OCF | 12.59 | ||
| P/B | 2.89 | ||
| P/tB | 12.4 | ||
| EV/EBITDA | 8.49 |
EPS(TTM)0.94
EY5.42%
EPS(NY)1.16
Fwd EY6.69%
FCF(TTM)1.36
FCFY7.84%
OCF(TTM)1.38
OCFY7.94%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.55
PEG (5Y)2.32
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.62 |
F-Score9
WACC7.2%
ROIC/WACC1.87
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year30.73%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
What is the valuation status for M12 stock?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for M12 stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 18.45 and the Price/Book (PB) ratio is 2.89.
What is the financial health of M1 KLINIKEN AG (M12.DE) stock?
The financial health rating of M1 KLINIKEN AG (M12.DE) is 8 / 10.